{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:51:54Z","timestamp":1777870314095,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While the use of different\u00a0immunosuppressants has been investigated in immunoglobulin A nephropathy, further investigation is needed to assess the effect of a regimen of mycophenolate mofetil combined with a short course of glucocorticosteroids in the subset of patients with histologically active features. We compared the efficacy and safety of a combined regimen of mycophenolate mofetil and glucocorticosteroids to a conventional regimen of glucocorticosteroids alone in patients with immunoglobulin A nephropathy who have active lesions and major urinary abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study involved 30 immunoglobulin A nephropathy patients with active histological lesions, 15 of whom were treated with both mycophenolate mofetil 2 g\/day for 6 months and 3 pulses of 15 mg\/kg methylprednisolone, followed by a short tapering schedule of oral prednisone. The control group was made up of the remaining 15 clinically- and histologically-matched patients treated with glucocorticosteroids alone according to a validated schedule, i.e., 1 g of methylprednisolone given intravenously for 3 consecutive days, followed by oral prednisone 0.5 mg\/kg every other day for 6 months. At diagnosis, all patients had urinary protein excretion\u2009&gt;\u20091\u00a0g\/24\u00a0h and microscopic hematuria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the end of the first year of follow-up (30 patients) and after 5\u00a0years (17 patients), there were no differences between the two groups in terms of urinary abnormalities and functional parameters. Both regimens achieved a statistically significant decrease in 24-h urinary protein excretion (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and a reduction of microscopic hematuria. However, the mycophenolate mofetil-based regimen allowed a cumulative sparing dose of 6\u00a0g of glucocorticosteroids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this single center study on immunoglobulin A nephropathy patients with active lesions and major urinary abnormalities and at increased risk of glucocorticosteroid-related complications, a mycophenolate mofetil-based regimen demonstrated similar outcomes in terms of complete response and relapse (at 1 and 5\u00a0years) compared to a conventional glucocorticosteroid-based protocol, while achieving a consistent reduction of glucocorticosteroid cumulative dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-023-01636-6","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T05:02:23Z","timestamp":1686546143000},"page":"2223-2231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy"],"prefix":"10.1093","volume":"36","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Careddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Naretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Quattrocchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"1636_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA (2013) IgA nephropathy. N Engl J Med 368:2402\u20132414","journal-title":"N Engl J Med"},{"key":"1636_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100:753\u2013779","journal-title":"Kidney Int"},{"key":"1636_CR3","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225\u20132236","journal-title":"N Engl J Med"},{"key":"1636_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883\u2013887","journal-title":"Lancet"},{"key":"1636_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L et al (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157\u2013163","journal-title":"J Am Soc Nephrol"},{"key":"1636_CR6","first-page":"796","volume":"82","author":"X Chen","year":"2002","unstructured":"Chen X, Chen P, Cai G et al (2002) A randomized control trial of Mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi 82:796\u2013801","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1636_CR7","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes BD, Oyen R, Claes K et al (2004) Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842\u20131849","journal-title":"Kidney Int"},{"key":"1636_CR8","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch G, Lin J, Rosenstock J et al (2005) Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 20:2139\u20132145","journal-title":"Nephrol Dial Transplant"},{"key":"1636_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","volume":"68","author":"SC Tang","year":"2005","unstructured":"Tang SC, Leung JC, Chan LY et al (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68:802\u2013812","journal-title":"Kidney Int"},{"key":"1636_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ki.2009.499","volume":"77","author":"SC Tang","year":"2010","unstructured":"Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN (2010) Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77:543\u2013549","journal-title":"Kidney Int"},{"key":"1636_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","volume":"66","author":"J Hogg","year":"2015","unstructured":"Hogg J, Bay RC, Jennette JC et al (2015) Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 66:783","journal-title":"Am J Kidney Dis"},{"key":"1636_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S0140-6736(05)60198-5","volume":"349","author":"R Nowack","year":"1997","unstructured":"Nowack R, Birck R, Van Der Woude FJ (1997) Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 349:774","journal-title":"Lancet"},{"key":"1636_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1046\/j.1523-1755.2002.00214.x","volume":"61","author":"MJ Choi","year":"2002","unstructured":"Choi MJ, Eustace JA, Gimenez LF et al (2002) Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098\u20131114","journal-title":"Kidney Int"},{"key":"1636_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12882-017-0647-x","volume":"18","author":"B Du","year":"2017","unstructured":"Du B, Jia Y, Zhou W, Min X, Miao L, Cui W et al (2017) Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis. BMC Nephrol 18:245","journal-title":"BMC Nephrol"},{"key":"1636_CR15","doi-asserted-by":"publisher","first-page":"i123","DOI":"10.1093\/ndt\/gfw326","volume":"32","author":"H Beckwith","year":"2017","unstructured":"Beckwith H, Medjeral-Thomas N, Galliford J et al (2017) Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. Nephrol Dial Transplant 32:i123\u2013i128","journal-title":"Nephrol Dial Transplant"},{"key":"1636_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5301\/JN.2011.8452","volume":"25","author":"D Roccatello","year":"2012","unstructured":"Roccatello D, Rossi D, Marletto F et al (2012) Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. J Nephrol 25:198\u2013203","journal-title":"J Nephrol"},{"key":"1636_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5414\/CP201887","volume":"52","author":"X Liu","year":"2014","unstructured":"Liu X, Dewei D, Sun S et al (2014) Treatment of severe IgA nephropathy: mycophenolate mofetil\/prednisone compared to cyclophosphamide\/prednisone. Int J Clin Pharmacol Ther 52:95\u2013102","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1636_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"JH Hou","year":"2017","unstructured":"Hou JH, Le WB, Chen N et al (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69:788\u2013795","journal-title":"Am J Kidney Dis"},{"key":"1636_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/ajkd.2002.31399","volume":"39","author":"O Hotta","year":"2002","unstructured":"Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y (2002) Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 39:493\u2013502","journal-title":"Am J Kidney Dis"},{"key":"1636_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40620-014-0165-x","volume":"28","author":"XH Shen","year":"2015","unstructured":"Shen XH, Liang SS, Chen HM et al (2015) Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol 28:441\u2013449","journal-title":"J Nephrol"},{"key":"1636_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0272-6386(00)70326-X","volume":"35","author":"T Shoji","year":"2000","unstructured":"Shoji T, Nakanishi I, Suzuki A et al (2000) Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 35:194\u2013201","journal-title":"Am J Kidney Dis"},{"key":"1636_CR22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3760\/cma.j.issn.0366-6999.20132396","volume":"127","author":"Y Liang","year":"2014","unstructured":"Liang Y, Zhang J, Liu D, Quan S, Xing G, Liu Z (2014) Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype. Chin Med J (Engl) 127:102\u2013108","journal-title":"Chin Med J (Engl)"},{"issue":"23","key":"1636_CR23","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B et al (2015) STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373(23):2225\u20133336","journal-title":"N Engl J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01636-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01636-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01636-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:37Z","timestamp":1777564357000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/8\/2223\/8304186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1636"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01636-6","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"2 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted according to the Piedmont and Aosta Valley (North-West Italy) legislation for Rare Diseases (N. 1577\/UC\/SAN of 11.10.2005 based on Regional Government Act 23 April 2007 dealing with Rare Diseases, Systemic Sclerosis RM0091; article. 1: 796 paragraph Z Law number 296 of 2006. Number 5-5740). The study was conducted according to the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient provided written consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}